

In the review **Reducing the immunostimulatory activity of CpG-containing plasmid DNA vectors for non-viral gene therapy**, published in the November 2004 issue of *Expert Opinion on Drug Delivery* (*Expert Opin. Drug Deliv.* (2004) 1(1):115-125), the following error has been brought to our attention:

The Y-axis in Figure 3 should read "Human Factor IX (ng/ml)" and not "Human Factor IX (mg/ml)".

In the Technology Evaluation **Adaptive Aerosol Delivery (AAD®) technology**, published in the November 2004 issue of *Expert Opinion on Drug Delivery* (*Expert Opin. Drug Deliv.* (2004) 1(1):165-176), the following errors have been brought to our attention:

The address on page 165 should read Respironics, Respiratory Drug Delivery Division, 41 Canfield Road, Cedar Grove, NJ 07009-1201, USA

On page 168, Omron Healthcare (Japan) should read Omron Healthcare (Kyoto, Japan)

On page 168, the sentence "I-neb can deliver a preset volume in the range 0.25 - 1.4 ml depending on the size of the I-neb metering chamber, which has a residual 0.1 ml" should read "I-neb can deliver a preset volume in the range 0.25 - 1.4 ml depending on the size of the I-neb metering chamber, which has a residual volume of 0.1 ml"

On page 168 and 170, Section 5 should read Section 6

On page 170, one-button press strategy should read single dose strategy

On page 171, mg/day should be replaced with mg q.d.

The Mimic Breathing Simulator should read MiMiC Breathing Emulator in all instances

The E-mail address of the author for correspondence is kurt.nikander@respironics.com

We sincerely regret any inconvenience or complications that this may have caused among our readers.